| |
| | [No title] |
 | | Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is characterized by a progressive degeneration of spinal cord and cerebral cortex motor neurons, leading to muscular atrophy, paralysis, respiratory failure, and death. |
 | | As a result of these developments, enthusiasm for the potential of VEGF as a therapeutic target Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is characterized by a progressive degeneration of spinal cord and cerebral cortex motor neurons, leading to muscular atrophy, paralysis, respiratory failure, and death. |
 | | While these findings are clearly remarkable, excitement for the arrival of approved human therapies must be tempered by the understanding that there is still very little known about the etiology of ALS much less the details of its molecular mechanisms and how these relate to mouse models of the disease. |
| www.rndsystems.com /cb_detail_objectname_FA04_VEGFAmyotrophic.aspx (756 words) |
|